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 Abstract  
Background: Prediction of diabetic retinopathy (DR) is important in countries where 
systematic screening programs for diabetic eye disease have not been established. 
This study aimed to identify the predictive value of cystatin C for DR in Chinese 
patients with type 2 diabetes.  
Subjects and Methods: Data from a cross-sectional hospital-based survey of 450 type 
2 diabetes patients were analyzed in the study. DR was assessed by 7-field 
stereoscopic retinal photography. Duration of diabetes and other related information 
were obtained by questionnaire. Blood pressure, HbA1c, cystatin C, glomerular 
filtration rate (GFR), urinary albumin excretion (UAE), and lipid were measured. 
Binary logistic regression was performed to evaluate potential risk factors for DR. 
The predictive value of related factors for DR was evaluated using ROC curve.  
Results: Cystatin C (OR: 2.004, P=0.023) was a risk factor for DR after GFR and 
other possibly related factors were adjusted. Cystatin C had a significant predictive 
value for DR (AUC: 0.763, P<0.001; optimal cut-off value: 1.11 mg/L, sensitivity: 
56.00%, specificity: 83.90%) or severe DR (AUC: 0.821, P<0.001; optimal cut-off 
value: 1.23 mg/L, sensitivity: 80.00%, specificity: 90.00%).  
Conclusions: Cystatin C is a novel risk factor for DR, and should be used to screen 
and forecast the presence of DR (especially severe DR) in Chinese patients with type 
2 diabetes. Moreover, the close association of cystatin C with DR does not depend on 
its superior ability in estimating GFR.  
  
 Introduction 
Diabetic retinopathy (DR) is a severe complication of diabetes and the leading 
cause of visual loss and blindness in the working aged population [1-2]. Cystatin C is 
a small protein that belongs to the cysteine proteinase family, and is produced by all 
nucleated cells at a constant rate. Due to its small size, cystatin C can be filtered by 
the glomerulus freely, and it is not secreted but is fully reabsorbed and broken down 
by the renal tubules. This means that the level of blood cystatin C is primarily 
determined by the glomerular filtration rate (GFR). Studies have shown that cystatin 
C is a superior marker of GFR. A large number of studies have focused on the 
relationship between cystatin C and diabetic nephropathy (DN), but few studies have 
analyzed the relationship between cystatin C and DR. A recent study indicated that 
cystatin C is an independent risk factor for DR, and high cystatin C levels predict 
sight-threatening diabetic retinopathy (STDR) in type 2 diabetes patients [3]. STDR, 
including severe non-proliferative diabetic retinopathy (severe NPDR), proliferative 
diabetic retinopathy (PDR), and clinically significant macular edema (CSME) [4], 
greatly contributes to visual loss in patients with diabetes. Systematic screening 
programs for diabetic eye disease mainly aim to screen for STDR. By means of the 
screening programs, patients with STDR can be diagnosed early and receive 
appropriate treatment (for example, laser photocoagulation). This is helpful to protect 
patient’s residual vision and to improve their quality of life. Unfortunately, in many 
developing countries, including China, the programs have not been developed. If 
cystatin C was capable of predicting STDR as reported, it could provide a promising 
 predictive parameter to doctors when they suggest that their diabetic patients should 
visit an ophthalmologist for further professional examination. However, existing 
epidemiological studies are insufficient for ascertaining the association between 
cystatin C and DR. DN and DR are microvascular complications of diabetes, and they 
have similar pathogenesis and risk factors. This indicates that the association between 
DN and DR should be close. Studies have found that cystatin C, as a superior marker 
of GFR, is a sensitive index to find the early phase of DN in patients with diabetes,
 
especially in those diabetic patients with normoalbuminuria [5-6].
 
One study also 
found that lower estimated GFR was significantly associated with the severity of DR 
in Chinese patients with type 2 diabetes mellitus [7]. If there was a close association 
between cystatin C and DR, it is reasonable to speculate that the association is 
probably only because cystain C is a sensitive index to estimate GFR. Therefore, three 
problems are not clear and are worth exploring. First, it is not clear whether cystatin C 
is a real risk factor for DR. Second, it is not clear whether cystatin C has any value in 
predicting DR. Third, it is not clear whether or not the effect of cystatin C on DR is 
dependent on GFR. The aims of this study were to further evaluate the effect of 
cystatin C on DR, and to identify the predictive value of cystatin C for DR, as well as 
to evaluate whether the effect of cystatin C on DR is independent of GFR. 
 
Subjects and Methods 
Subject selection 
 Four hundred and fifty patients with type 2 diabetes were recruited from the 
Diabetes Centre of Dezhou People’s Hospital from January 2012 to December 2013. 
Type 2 diabetes mellitus was diagnosed according to the 1999 World Health 
Organization criteria. The exclusion criteria of study subjects was as follows: (1) type 
1 diabetes; (2) specific type diabetes or gestational diabetes mellitus; (3) with definite 
history of DR; (4) with acute complications of diabetes (such as infection or diabetic 
ketoacidosis); (5) with serious hepatic disease; (6) with acute or serious 
cardiovascular disease; (7) trauma or other definite causes and secondary nephropathy 
(such as glomerular nephritis, pyelonephritis, nephrolithiasis, or lupus nephritis); (8) 
retinopathy caused by hypertension; (9) with contraindications to perform
 
99m
Tc-DTPA dynamic renal imaging. The study was approved by the Human 
Research and Ethics Committee of Dezhou People’s Hospital, and all participants 
signed informed consents that adhered to the tenets of the declaration of Helsinki. 
   
Data collection and Measurements 
Information on gender, age, duration of diabetes, family history of diabetes, history 
of smoking, history of hypertension, and history of DR were obtained using a 
questionnaire. According to 7-field stereoscopic retinal photography, patients were 
classified as: no diabetic retinopathy (NDR); mild non-proliferative diabetic 
retinopathy (mild NPDR); moderate non-proliferative diabetic retinopathy (moderate 
NPDR); severe DR, including severe NPDR or PDR [8]. Blood pressure was 
measured. Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, 
 diastolic blood pressure (DBP) ≥90mmHg, or with definite history of hypertension. 
Venous blood samples were drawn from all patients after an overnight fast. The 
concentration of serum cystatin C was measured by a highly sensitive latex-enhanced 
immunoturbidimetric method. GFR was assessed using
 99m
Tc-diethylene triamine 
pentaacetic acid (DTPA) dynamic renal imaging (Gates method). Low-pressure liquid 
ion exchange and a flowing colorimetric method were performed to measure 
glycosylated hemoglobin (HbA1c). Total cholesterol (TC) and triglyceride (TG) were 
measured by an enzyme-coupling colorimetric method. High-density lipoprotein 
cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured 
by a direct method. An immunoturbidimetric method was used to measure 
apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), and UAE. The ratio of 
AopA1/ApoB was calculated.  
The continuous variables were categorized in the following way: Age （years）: <40, 
~40, ~50, ~60; Duration of diabetes (years): <5, ~5, ~10, ~15; HbA1c (%) : <7.5, ~7.5, 
~9.0, ~10.5, ~12.0; GFR (ml/min/1.73m
2): ≥90 (normal), 60–89 (slight decrease), 
30–59 (moderate decrease), ≤29 (severe decrease or end-stage chronic kidney 
disease) [9]; cystatin C (mg/L): <0.80, ~0.80, ~1.00, ~1.20 (categories were based on 
quartiles); UAE: (mg/24 h): <30 (normoalbuminuria), 30–300 (microalbuminuria), 
≥300 (macroalbuminuria) [10]. Lipids were categorized according to the National 
Cholesterol Education Program, Adult Treatment Panel (NCEP APT) [11]: TC 
(mmol/L): <5.2, ≥5.2; TG (mmol/L): <1.7, ≥1.7; HDL-C (mmol/L): >1.0, ≤1.0；
 LDL-C (mmol/L): <2.6, ≥2.6. ApoA1/ApoB: ≥1.4, 1.2-<1.4, 1.0-<1.2, 0.8-<1.0, 
<0.8； 
 
Statistical Analysis  
Continuous variables were tested for normal distribution by the 
Kolmogorov–Smirnov test. The normal distributed continuous variables are described 
as the mean ± SD, and those non-parametrically distributed are shown as the median 
(inter-quartile range). Discrete variables are presented as frequencies (percentages). 
Comparisons of the groups for normally distributed continuous variables were 
performed by one-way ANOVA. The comparison of discrete variables was performed 
by the Chi-square test (R×C tables). Binary logistic regression was performed to 
evaluate the risk factors of DR. The variables that were proven to be significant in the 
univariate analysis were entered (method: Forward: LR) as independent variables in 
the regression model. Bivariate correlation analysis of Spearman was performed to 
evaluate the correlation between cystatin C and the severity level of DR. The ability 
of related factors in predicting DR was evaluated using a ROC curve. All statistical 
analyses above used SPSS 16.0. Statistical Software ROCKIT0.9β was performed to 
assess the difference of area under the ROC curve (AUC). All P-values were 
two-sided, and a P-value of <0.05 was considered statistically significant. 
  
Results 
 Four hundred and fifty patients including 267 males (59.33%) and 183 females 
(40.67%) were involved in this study. The mean age was 55.17±10.32 years old, and 
the median (inter-quartile) duration of diabetes was 6.00 (2–11) years. Of the 450 
patients, 60 (13.33%) had mild NPDR, 51 (11.33%) had moderate NPDR, 39 (8.67%) 
had severe NPDR, and 21(4.67%) had PDR. The prevalence of DR was 38.00%.  
Between patients with and without DR, there were significant differences in age, 
duration of diabetes, hypertension, HbA1c, cystatin C, GFR, UAE, TC, TG, LDL-C, 
and ApoA1/ApoB (all P<0.01; Table 1). Of these variables, duration of diabetes, 
HbA1c, cystatin C, hypertension, GFR, and ApoA1/ApoB retained their significant 
associations with the presence of DR in the binary logistic regression model (all 
P<0.05; Table 2).  
The serum concentration of cystatin C was significantly different among patients 
with different severity levels of DR (F=12.667, P<0.001), and an increasing tendency 
of the concentration of cystatin C was shown with the increase in the severity level of 
DR (Fig. 1). There was a positive correlation between cystatin C and the severity level 
of DR (r=0.534, P<0.001; Table 3).  
Cystatin C (AUC: 0.763, P<0.001, 95%CI: 0.681–0.846), duration of diabetes 
(AUC: 0.787, P<0.001, 95%CI: 0.708–0.865), and HbA1C (AUC: 0.714, P<0.001, 
95%CI: 0.629–0.800) had significant value in predicting DR (Fig. 2). The optimal 
cut-off value of cystatin C in predicting DR was 1.11 mg/L (sensitivity: 56.00%, 
specificity: 83.90%, Yoden index: 0.40). There were no significant differences for the 
AUC between cystatin C, HbA1c, and duration of diabetes (P>0.05; Table 4). 
 Cystatin C was significant (AUC: 0.821, P<0.001, 95%CI: 0.692–0.950) for 
predicting the presence of severe DR (severe NPDR or PDR), and the optimal cut-off 
value was 1.23 mg/L (sensitivity: 80.00%; specificity: 90.00%, Yoden index: 0.70) 
(Fig. 3). 
 
Discussion  
This study found that cystatin C was a risk factor for DR after GFR and other 
potentially related variables were adjusted. The morbidity of DR increased by 2.004 
times with every 0.2 mg/L increase in cystatin C. This suggests that cystatin C is a 
stronger risk factor of DR, and the close association of cystatin C with DR does not 
depend on its superior ability in estimating GFR. However, why there is a close 
association between cystatin C and DR is not clear. The pathophysiologic changes of 
DR include edema of the macula, retinal inflammation, neovascularization, and optic 
neuropathy [12-15], and cystatin C likely plays an important role in these 
pathophysiologic changes. Retinal pigment epithelium (RPE) was identified as a 
major site for secretion of cystatin C, which is involved in the mechanisms of macular 
degeneration [16]. The neuroretina was found to be a high-affinity system, and human 
cystatin C injected intravitreally into normal rat eyes can be taken up into cells of the 
neuroretina and into the retinal pigment [17]. We speculate that there is perhaps a 
similar system in humans through which higher serum cystatin C could be taken up 
into the retinal pigment. Cystatin C plays an important role in inflammation and 
increases the levels of C-reactive protein (CPR) [18] and homocysteine (Hcy) [19], 
 which is involved in the impairment of the microvasculature. Cystatin C is also 
speculated to be involved in arterial wall remodeling, blood vessel integrity, 
neovascularization, and neuronal degenerative pathology [20]. These mechanisms 
mentioned above, involving cystatin C and DR, might partly explain the close 
association between them. Increasing evidence shows that traditional risk factors 
(such as diabetes duration and HbA1c) do not fully explain a patient’s risk of having 
DR [21]. Our findings indicate that cystatin C is a novel risk factor for DR, which 
probably partly solves this question.   
It has been well established that duration of diabetes and the control of glucose are 
the strongest risk factors for DR, but there were no significant differences when the 
AUCs were compared between cystatin C, duration of diabetes, and HbA1c in our 
study. This indicates that the ability of cystatin C in predicting DR should be superior. 
However, the optimal cut-off value (1.11 mg/L) is not ideal. Despite the higher 
specificity (83.90%), the sensitivity (56.00%) is lower. In our study, cystatin C had a 
more ideal cut-off point in predicting severe DR. Sensitivity and specificity were 
80.00% and 90.00%, respectively, when the optimal cut-off point was 1.23 mg/L. 
This indicates that cystatin C seems to be a better predictive marker for severe DR 
and higher cystatin C levels are more capable of discriminating severe DR in patients 
with type 2 diabetes mellitus. This study found that cystatin C significantly correlated 
with the severity level of DR, and this probably explains why cystatin C was superior 
in predicting severe DR. DR, especially severe DR, can result in severe and 
irreversible visual loss. Except for common treatments (such as strict control of blood 
 glucose, and blood pressure and lipids), laser photocoagulation is the first and most 
effective option for treatment for DR. The Early Treatment Diabetic Retinopathy 
Study (ETDRS) showed that laser photocoagulation can reduce the progression of DR 
[22] and the risk of vision loss from PDR [23]. ETDRS also examined the effect of 
treating eyes with mild NPDR to early PDR, and suggested that scattered 
photocoagulation could be deferred at the stage of mild-to-moderate NPDR because 
the rate of visual loss was low with either treatment of photocoagulation applied early 
or delayed. When DR is more severe, photocoagulation should not be delayed. 
Therefore, early diagnosis of severe DR is very important for initiating effective laser 
photocoagulation. However, systematic screening programs for diabetic retinopathy 
have not been developed in many developing and poor countries (including China). 
Many diabetic patients with severe DR cannot be diagnosed in time, and so they do 
not undergo timely and effective treatment (especially laser photocoagulation). This 
results in the progression of visual loss, and even blindness. In fact, most of the 
patients with diabetes always visit an endocrinologist, but not an ophthalmologist 
unless their eyes have significant visual abnormality. Therefore, it is critical that 
endocrinologists suggest their patients visit an ophthalmologist to find existing DR, 
especially severe DR. It is helpful for those patients with severe DR to avoid further 
visual loss by means of the early diagnosis and appropriate initiation of 
photocoagulation. According to the optimal cut-off point of cystatin C in predicting 
severe DR, a concrete predictive index should be provided to endocrinologists when 
they suggest their patients with type 2 diabetes visit an ophthalmologist for further 
 professional examination. Moreover, the measurement of cystatin C is more 
convenient and economical than retinal photographs. Considering the growing 
financial burden of diabetes, cystatin C may be a promising biomarker in screening 
and forecasting the presence of severe DR. 
In our study, the morbidity of DR increased by 3.823-fold with every 30 
ml/min/1.73m
2
 decrease of GFR. This indicates that GFR is an important protective 
factor for DR. The decrease of GFR is characteristic of diabetic nephropathy, and loss 
of GFR often occurs before the onset of microalbuminuria in type 2 diabetes mellitus 
[24]. Most previous studies only used albuminuria as a criterion to evaluate the 
existence of DN, which probably underestimated the association between DN with 
DR. Our study also found that the ratio of ApoA1/ApoB was significantly associated 
with DR. The morbidity of DR increased by 2.552-fold with every 0.2 decrease in the 
ratio of ApoA1/ApoB in our study. This suggests that serum ApoA1/ApoB 
measurement could be a new index of DR progression. Recently, several studies 
revealed that ApoA1, ApoB, ApoA1/ApoB, or ApoB/ApoA1 were significantly 
associated with DR [25-27]. TG, TC, or LDL-C did not show any significant 
associations with DR in a logistic regression model, which indicates that 
ApoA1/ApoB is probably more important than these lipid constituents in the 
progression of DR.  
It is well known that duration of diabetes, the control of glucose and blood pressure 
are the traditional risk factors for DR [28]. Our study also found that duration of 
diabetes, HbA1c, and hypertension were significantly associated with DR. The 
 morbidity of DR increased by 2.030-fold with every increase of 5 years' disease 
duration, and by 2.169-fold with every 1.5% increase in HbA1c. Compared with 
diabetic patients without hypertension, 3.588 folds increase in patients accompany 
with hypertension. This further indicates that they play very important roles in the 
occurrence and progression of DR.  
One advantage of this study was the rigorous inclusion criteria of subjects, which 
decreased the disturbance of some related confounding factors. However, the 
cross-sectional nature of the study limits the sequential of our finding. Moreover, the 
single source of study subjects is also a limitation. Subjects of this study only came 
from one diabetes center, which perhaps resulted in the number of severe DR 
(especially severe PDR) being less because many patients with severe DR visited the 
department of ophthalmology. This probably underestimated the association between 
cystatin C and DR. More epidemiologic (especially multicenter studies and 
prospective studies) and pathophysiological studies should be designed so that the 
association of cystatin C with DR can be confirmed. 
In conclusion，cystatin C is a novel risk factor for DR, and should be used to screen 
and forecast the presence of DR (especially severe DR) in Chinese patients with type 
2 diabetes. Moreover, the close association of cystatin C with DR does not depend on 
its superior ability in estimating GFR.  
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 Table 1. Characteristics of NDR and DR subjects. 
Variables  NDR (n=279) DR (n=171) χ
2
 P value 
Gender (male/female) 168/111 99/72 0.237 0.627 
Age (group 1/2/3/4) 33/60/90/78 6/24/72/87 25.75 0.000 
Duration of diabetes (group 1/2/3/4) 168/84/18/12 33/45/42/48 112.00 0.000 
Family history of diabetes (no/yes) 174/105 99/72 0.888 0.346 
Hypertension (no/yes) 144/135 54/117 17.27 0.000  
History of smoking (no/yes) 201/78 117/54 0.671 0.413 
HbA1c (group 1/2/3/4/5) 57/87/72/51/12 9/39/33/48/42 62.10 0.000 
Cystatin C (group 1/2/3/4) 84/108/75/12 12/36/39/84 137.40 0.000 
GFR (group 1/2/3/4)
 
 225/72/8/2 64/42/27/10 61.65 0.000 
UAE (group 1/2/3) 114/128/27 21/75/75 84.22 0.000 
TC (group 1/2) 189/90 93/78 8.084 0.004 
TG (group 1/2) 174/105 90/81 4.143 0.042 
LDL-C (group 1/2) 219/60 114/57 7.709 0.005 
HDL-C (group 1/2) 171/108 105/66 0.001 0.981 
ApoA1/ApoB (group 1/2/3/4/5) 21/104/100/41/13 3/25/80/46/17 41.387 0.000 
Age (years): group 1: <40, group 2: ~40, group 3: ~50, group 4: ~60; Duration of 
diabetes (years): group 1: <5, group 2: ~5, group 3: ~10, group 4: ~15; HbA1c (%): 
group 1: <7.5, group 2: ~7.5, group 3: ~9.0, group 4: ~12.0; GFR (ml/min/1.73m
2
): 
group 1: ≥90, group 2: 60–89, group 3: 30–59, group 4: ≤29; Cystatin C (mg/L): 
group 1: <0.80，group 2: ~0.80，group 3: ~1.00, group 4: ~1.20; UAE: (mg/24 h): 
 group 1: <30, group 2: 30–300, group 3: ≥300; TC (mmol/L): group 1: <5.2, group2: 
≥5.2; TG (mmol/L): group 1: <1.7, group 2: ≥1.7; HDL-C (mmol/L): group1: >1.0, 
group 2 ≤1.0; LDL-C(mmol/L): group 1: <2.6, group 2: ≥2.6. ApoA1/ApoB: group 1: 
≥1.4 , group 2: 1.2-<1.4, group 3: 1.0-<1.2, group 4: 0.8-<1.0, group 5:<0.8. NDR, no 
diabetic retinopathy; DR, diabetic retinopathy; HbA1c, glycosylated hemoglobin; GFR, 
glomerular filtration rate; UAE: urinary albumin excretion; TC, total cholesterol; TG, 
triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density 
lipoprotein cholesterol; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 2. Associations of risk markers with DR (binary logistic regression model). 
Variables Measurement OR (95.0% CI) P value 
Duration of diabetes Per SD (5 years) increase 2.030（1.203, 3.425） 0.008 
HbA1C Per SD (1.5%) increase 2.169（1.370, 3.433） 0.001 
Cystatin C Per SD (0.2mg/L) increase 2.004（1.103, 3.643） 0.023 
ApoA1/ApoB Per SD (0.2) decrease 2.552（1.378, 4.727） 0.003 
GFR Per SD (30 ml/min/1.73m
2
) decrease 3.823（1.541, 9.487） 0.004 
Hypertension No or Yes 3.588（1.162, 11.077） 0.026 
Model simultaneously contained age, duration of diabetes, hypertension, HbA1C, 
cystatin C, GFR, UAE, TG, TC, LDL-C, and ApoA1/ApoB. age, UAE, TG, TC, and 
LDL-C were not in the equation of the binary logistic regression model at the last step 
(all P>0.05). HbA1c, glycosylated hemoglobin; GFR, glomerular filtration rate; 
ApoA1, apolipoprotein A1; ApoB, apolipoprotein B. 
 
 
 
 
 
 
 
 
 Table 3. Frequency distribution of DR with different severity levels among groups of 
cystatin C. 
a
 Patients were categorized in quartiles based on the cystatin C (mg/L).
 b 
Including 
severe NPDR and PDR. NDR, no diabetic retinopathy; Mild NPDR, mild 
non-proliferative diabetic retinopathy; Moderate NPDR, moderate non-proliferative 
diabetic retinopathy; Severe NPDR, severe non-proliferative diabetic retinopathy; 
PDR, proliferative diabetic retinopathy. 
 
 
 
 
 
 
 
 
 
 
Cystatin C (mg/L)
a
 NDR Mild NPDR Moderate NPDR Severe DR 
b
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
<0.80 84 (87.50%) 6 (6.25%） 3 (3.13%) 3 (3.13%) 
~0.80 108 (75.00%) 21 (14.58%） 12 (8.33%) 3 (2.08 %) 
~1.00 75 (65.79%) 18 (15.79%） 15 (13.16%) 6 (5.26%) 
~1.20 12 (12.50%) 15 (15.63%) 21 (21.87%) 48 (50.00%) 
 Table 4. Comparison of AUC between different predictive markers. 
Predictive markers Z value 
P value 
(two-sided) 
95%CI of AUC difference 
Lower Upper 
Cystatin C and duration of 
diabetes 
-0.5188 0.6039 -0.1176 0.0684 
HbA1c and cystatin C -0.6496 0.5160 -0.1594 0.0800 
HbA1c and duration of 
diabetes 
-1.1213 0.2622 -0.1768 0.0481 
AUC, area under the curve; HbA1c, glycosylated hemoglobin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure legends: 
 
Fig 1. Cystatin C in patients with NDR, mild NPDR, moderate NPDR, and severe DR.
 
a 
Compared with moderate NPDR (P=0.012), mild NPDR (P=0.001), or NDR 
(P<0.001), there were significant differences;
 b 
Compared with NDR (P=0.017), there 
was a significant difference. NDR, no diabetic retinopathy; Mild NPDR, mild 
non-proliferative diabetic retinopathy; Moderate NPDR, moderate non-proliferative 
diabetic retinopathy; Severe NPDR, severe non-proliferative diabetic retinopathy; 
PDR, proliferative diabetic retinopathy. 
 
Fig. 2. ROC curve of different markers in predicting DR. DR, diabetic retinopathy; 
HbA1c, and glycosylated hemoglobin. 
 
Fig. 3. ROC curve of cystatin C in predicting severe DR (severe NPDR or PDR). 
Severe NPDR, severe non-proliferative diabetic retinopathy; PDR, proliferative 
diabetic retinopathy. 
 
 
 
